Abeona Therapeutics Inc. (NASDAQ:ABEO) had its target price raised by analysts at Cantor Fitzgerald from $21.00 to $34.00 in a research report issued to clients and investors on Wednesday. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 70.43% from the stock’s previous close.

A number of other research analysts have also recently issued reports on ABEO. Jefferies Group LLC restated a “buy” rating and issued a $22.00 target price on shares of Abeona Therapeutics in a research report on Thursday, June 22nd. BidaskClub upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Tuesday, July 11th. Maxim Group restated a “buy” rating and issued a $17.00 target price (up previously from $14.00) on shares of Abeona Therapeutics in a research report on Tuesday, July 18th. Finally, HC Wainwright set a $20.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $21.44.

Abeona Therapeutics (ABEO) traded down 2.882% during trading on Wednesday, reaching $19.375. The company had a trading volume of 3,043,598 shares. The firm’s market capitalization is $780.56 million. The stock has a 50 day moving average price of $14.58 and a 200 day moving average price of $8.49. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.21 million. On average, equities research analysts predict that Abeona Therapeutics will post ($0.68) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Increases Abeona Therapeutics Inc. (ABEO) Price Target to $34.00” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/11/cantor-fitzgerald-increases-abeona-therapeutics-inc-abeo-price-target-to-34-00.html.

Hedge funds have recently added to or reduced their stakes in the stock. Family Management Corp bought a new stake in Abeona Therapeutics in the first quarter valued at $120,000. State of Wisconsin Investment Board bought a new stake in Abeona Therapeutics in the second quarter valued at $122,000. Rhumbline Advisers bought a new stake in Abeona Therapeutics in the second quarter valued at $190,000. Bank of New York Mellon Corp increased its stake in Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 23,358 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new stake in Abeona Therapeutics in the second quarter valued at $264,000. Institutional investors and hedge funds own 38.38% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.